Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
German-Polish man charged with calling for attacks on top politicians- A Lone Wolf Outsmarted Hunters in the Black Forest and Then Vanished
- 2025 Arctic League telethon raises more than $39k
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- Timex Gives Its Classic Affordable Field Watch a Tactical, Milspec Makeover
- Examination In progress into Abuse of Japanese Government-Supported Advance
- ‘Grit’ and relentless perseverance can take a toll on brain health − particularly for people facing social stresses like racism
- Nvidia Share Price Could Be Hit Hard By Iran War
